What Is the BDC Life Sciences Venture Fund?
The Business Development Bank of Canada (BDC) has announced the launch of a $150 million Life Sciences Venture Fund. This fund specifically targets early-stage companies operating in therapeutics and medical technologies. Moreover, it marks a significant step toward strengthening Canada’s domestic life sciences ecosystem.
The fund is structured to deliver patient capital — long-horizon investment suited to the slow, science-driven timelines of biotech and MedTech development. As a result, it primarily supports companies at the seed and Series A stages, helping them move confidently from research and development into commercialization.
Why Canada’s Life Sciences Sector Needs This Fund
A Sector With Enormous Economic Impact
Canada’s life sciences industry already contributes $18.3 billion annually to the national economy. Furthermore, it supports more than 135,000 specialized jobs across the country. These numbers reflect a sector with proven strength and long-term venture capital returns.
The Funding Gap Holding Companies Back
Despite this strong foundation, early-stage companies consistently struggle to attract sufficient capital. Investors often overlook seed and Series A life sciences companies because of long development cycles and demanding scientific validation requirements. Consequently, many promising Canadian innovations fail to reach the market — or worse, they depend on foreign investment to survive.
BDC’s new fund directly addresses this gap. By stepping in at the earliest stages, it reduces Canada’s reliance on international capital and strengthens economic sovereignty at home.
Who Leads the Fund?
Parimal Nathwani Appointed Managing Partner
BDC has appointed Parimal Nathwani as Managing Partner of the Life Sciences Venture Fund. Nathwani brings more than 20 years of experience in building and scaling biotechnology and medical technology companies. His background spans scientific development, commercialization strategy, and operational leadership — making him well-suited to guide early-stage founders through complex growth challenges.
What the Fund Will Focus On
The fund targets two primary verticals:
- Therapeutic products — companies developing novel drugs, biologics, and treatment platforms
- Medical technologies — companies advancing devices, diagnostics, and digital health tools
Beyond capital deployment, the fund aims to translate Canadian research and intellectual property into globally competitive businesses. Therefore, it focuses on companies with strong scientific foundations and realistic paths to commercialization.
Additionally, the fund prioritizes Canadian companies that create high-quality jobs, improve health outcomes, and reinforce the country’s broader innovation ecosystem. In short, it serves both a financial and a national mission.
Key Quotes From BDC Leaders
Geneviève Bouthillier, Executive Vice President, BDC Capital, stated that life sciences is one of Canada’s most innovative sectors — yet early-stage companies continue to be overlooked by investors. She emphasized that Canada must build its own economic sovereignty through domestic champions, and that the $150 million fund signals a clear national intent to lead in life sciences from within.
Parimal Nathwani, Managing Partner, Life Sciences Venture Fund, acknowledged that Canada has world-class talent and a strong innovation base. However, he noted that the early-stage funding gap — combined with long development cycles and rigorous scientific demands — makes the need for targeted capital especially urgent. The fund, he said, aims to turn Canadian research into globally competitive businesses that generate real economic and human health impact.
What This Means for Canadian Innovation
The BDC Life Sciences Venture Fund sends a strong signal to both the scientific community and the investment world. First, it acknowledges that Canada’s innovation engine needs domestic fuel to thrive. Second, it demonstrates that government-backed capital can play a strategic role in filling gaps that private investors leave behind.
For early-stage founders in therapeutics and MedTech, this fund opens a credible, patient pathway to growth. For Canada’s economy, it represents a deliberate choice to build globally competitive health companies at home — rather than watching them migrate to better-funded markets abroad.
As the life sciences sector continues to evolve, initiatives like this one will prove critical to keeping Canada competitive on the world stage.
